메뉴 건너뛰기




Volumn 16, Issue 3, 2015, Pages 4985-4996

Faldaprevir for the treatment of hepatitis C

Author keywords

Chronic hepatitis C; Direct acting antivirals; Faldaprevir; Genotype 1; Protease inhibitor

Indexed keywords

CD81 ANTIGEN; CLAUDIN 1; CYSTEINE PROTEINASE; DELEOBUVIR; DIARRHEA; FALDAPREVIR; LOW DENSITY LIPOPROTEIN RECEPTOR; NAUSEA AND VOMITING; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; OCCLUDIN; PEGINTERFERON; PHOTOSENSITIVITY; RASH; RIBAVIRIN; SCAVENGER RECEPTOR BI; SERINE PROTEINASE; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; N-((CYCLOPENTYLOXY)CARBONYL)-3-METHYLVALYL-4-((8-BROMO-7-METHOXY-2-(2-((2-METHYLPROPANOYL)AMINO)-1,3-THIAZOL-4-YL)QUINOLIN-4-YL)OXY)-N-(1-CARBOXY-2-ETHENYLCYCLOPROPYL)PROLINAMIDE; NS3 PROTEIN, HEPATITIS C VIRUS; NS4 PROTEIN, HEPATITIS C VIRUS; OLIGOPEPTIDE; PEG-IFN-SA; THIAZOLE DERIVATIVE; VIRUS PROTEIN;

EID: 84925871791     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16034985     Document Type: Review
Times cited : (13)

References (40)
  • 2
    • 0036828784 scopus 로고    scopus 로고
    • The burden of hepatitis C in United States
    • Kim, W.R. The burden of hepatitis C in United States. Hepatology 2002, 36, S30–S34.
    • (2002) Hepatology , vol.36 , pp. S30-S34
    • Kim, W.R.1
  • 3
    • 77958105927 scopus 로고    scopus 로고
    • New antiviral therapies for chronic hepatitis C. Hepatol
    • Kanda T.; Imazeki, F.; Yokosuka, O. New antiviral therapies for chronic hepatitis C. Hepatol. Int. 2010, 4, 548–561.
    • (2010) Int , vol.4 , pp. 548-561
    • Kanda, T.1    Imazeki, F.2    Yokosuka, O.3
  • 4
    • 84892529894 scopus 로고    scopus 로고
    • EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
    • European Association for Study of Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J. Hepatol. 2014, 60, 392–420.
    • (2014) J. Hepatol , vol.60 , pp. 392-420
  • 5
    • 84884257232 scopus 로고    scopus 로고
    • Treatment of hepatitis C virus infection in the future
    • Kanda T.; Yokosuka, O.; Omata, M. Treatment of hepatitis C virus infection in the future. Clin. Transl. Med. 2013, 2, 9.
    • (2013) Clin. Transl. Med , vol.2 , pp. 9
    • Kanda, T.1    Yokosuka, O.2    Omata, M.3
  • 14
    • 84925879207 scopus 로고    scopus 로고
    • Available online, accessed on 1 March 2014
    • U.S. Food and Drug Administration. Available online: http://www.fda.gov/newsevents/newsroom/ pressannouncements/ucm376449.htm(accessed on 1 March 2014).
  • 15
    • 84925867662 scopus 로고    scopus 로고
    • Available online: (accessed on 1 March 2014)
    • U.S. Food and Drug Administration. Available online: http://www.fda.gov/forconsumers/byaudience/ forpatientadvocates/ucm377920.htm (accessed on 1 March 2014).
  • 17
    • 0033429914 scopus 로고    scopus 로고
    • Molecular virology of the hepatitis C virus
    • De Francesco, R. Molecular virology of the hepatitis C virus. J. Hepatol. 1999, 31, 47–53.
    • (1999) J. Hepatol , vol.31 , pp. 47-53
    • De Francesco, R.1
  • 18
    • 84905961801 scopus 로고    scopus 로고
    • The elusive function of the hepatitis C virus p7 protein
    • Atoom, A.M.; Taylor, N.G.; Russell, R.S. The elusive function of the hepatitis C virus p7 protein. Virology 2014, 462, 377–387.
    • (2014) Virology , vol.462 , pp. 377-387
    • Atoom, A.M.1    Taylor, N.G.2    Russell, R.S.3
  • 19
    • 79961213651 scopus 로고    scopus 로고
    • Progress toward development of a hepatitis C vaccine with broad shoulders
    • Ray, R. Progress toward development of a hepatitis C vaccine with broad shoulders. Sci. Transl. Med. 2011, 3, doi:10.1126/scitranslmed.3002772.
    • (2011) Sci.Transl. Med , pp. 3
    • Ray, R.1
  • 23
    • 34848881891 scopus 로고    scopus 로고
    • Ultra-rapid cardiotoxicity of hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse
    • Vanwolleghem, T.; Meuleman, P.; Libbrecht, L.; Roskams, T.; de Vos, R.; Leroux-Roels, G. Ultra-rapid cardiotoxicity of hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse. Gastroenterology 2007, 133, 1144–1155.
    • (2007) Gastroenterology , vol.133 , pp. 1144-1155
    • Vanwolleghem, T.1    Meuleman, P.2    Libbrecht, L.3    Roskams, T.4    De Vos, R.5    Leroux-Roels, G.6
  • 24
    • 79953224799 scopus 로고    scopus 로고
    • Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection
    • Manns, M.P.; Bourliere, M.; Benhamou, Y.; Pol, S.; Bonacini, M.; Trepo, C.; Wright, D.; Berg, T.; Calleja, J.L.; White, P.W., et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J. Hepatol. 2011, 54, 1114–1122.
    • (2011) J. Hepatol , vol.54 , pp. 1114-1122
    • Manns, M.P.1    Bourliere, M.2    Benhamou, Y.3    Pol, S.4    Bonacini, M.5    Trepo, C.6    Wright, D.7    Berg, T.8    Calleja, J.L.9    White, P.W.10
  • 25
    • 84878992253 scopus 로고    scopus 로고
    • Faldaprevir combined with pegylated interferon α-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV: SILEN-C1 Trial
    • Sulkowski, M.S.; Asselah, T.; Lalezari, J.; Ferenci, P.; Fainboim, H.; Leggett, B.; Bessone, F.; Mauss, S.; Heo, J.; Datsenko, Y., et al. Faldaprevir combined with pegylated interferon α-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV: SILEN-C1 Trial. Hepatology 2013, 57, 2143–2154.
    • (2013) Hepatology , vol.57 , pp. 2143-2154
    • Sulkowski, M.S.1    Asselah, T.2    Lalezari, J.3    Ferenci, P.4    Fainboim, H.5    Leggett, B.6    Bessone, F.7    Mauss, S.8    Heo, J.9    Datsenko, Y.10
  • 26
    • 84878980518 scopus 로고    scopus 로고
    • Faldaprevir combined with peginterferon α-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 Trial
    • Sulkowski, M.S.; Bourliere, M.; Bronowicki, J.P.; Asselah, T.; Pawlotsky, J.M.; Shafran, S.D.; Pol, S.; Mauss, S.; Larrey, D.; Datsenko, Y., et al. Faldaprevir combined with peginterferon α-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 Trial. Hepatology 2013, 57, 2155–2163.
    • (2013) Hepatology , vol.57 , pp. 2155-2163
    • Sulkowski, M.S.1    Bourliere, M.2    Bronowicki, J.P.3    Asselah, T.4    Pawlotsky, J.M.5    Shafran, S.D.6    Pol, S.7    Mauss, S.8    Larrey, D.9    Datsenko, Y.10
  • 27
    • 84890126935 scopus 로고    scopus 로고
    • Safety and efficacy of faldaprevir with pegylated interferon α-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection
    • Nishiguchi, S.; Sakai, Y.; Kuboki, M.; Tsunematsu, S.; Urano, Y.; Sakamoto, W.; Tsuda, Y.; Steinmann, G.; Omata, M. Safety and efficacy of faldaprevir with pegylated interferon α-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection. Liver Int. 2013, 34, 78–88.
    • (2013) Liver Int , vol.34 , pp. 78-88
    • Nishiguchi, S.1    Sakai, Y.2    Kuboki, M.3    Tsunematsu, S.4    Urano, Y.5    Sakamoto, W.6    Tsuda, Y.7    Steinmann, G.8    Omata, M.9
  • 28
    • 81855228070 scopus 로고    scopus 로고
    • Efficacy of the protease inhibitor BI 20135, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection
    • Zeuzem, S.; Asselah, T.; Angus, P.; Zarski, J.P.; Larrey, D.; Müllhaupt, B.; Gane, E.; Schuchmann, M.; Lohse, A.; Pol, S., et al. Efficacy of the protease inhibitor BI 20135, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 2011, 141, 2047–2055.
    • (2011) Gastroenterology , vol.141 , pp. 2047-2055
    • Zeuzem, S.1    Asselah, T.2    Angus, P.3    Zarski, J.P.4    Larrey, D.5    Müllhaupt, B.6    Gane, E.7    Schuchmann, M.8    Lohse, A.9    Pol, S.10
  • 31
  • 32
    • 80053339008 scopus 로고    scopus 로고
    • An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
    • Ghany, M.G.; Nelson, D.R.; Strader, D.B.; Thomas, D.L.; Seeff, L.B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54, 1433–1444.
    • (2011) Hepatology , vol.54 , pp. 1433-1444
    • Ghany, M.G.1    Nelson, D.R.2    Strader, D.B.3    Thomas, D.L.4    Seeff, L.B.5
  • 34
    • 84924065501 scopus 로고    scopus 로고
    • Role of IL28B genotype in older hepatitis C virus-infected patients. World
    • Kanda T.; Nakamoto, S.; Wu, S.; Yokosuka, O. Role of IL28B genotype in older hepatitis C virus-infected patients. World J. Immunol. 2013, 3, 54–61.
    • (2013) J. Immunol , vol.3 , pp. 54-61
    • Kanda, T.1    Nakamoto, S.2    Wu, S.3    Yokosuka, O.4
  • 36
    • 84931568272 scopus 로고    scopus 로고
    • HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b
    • in press
    • Hirotsu, Y.; Kanda T.; Matsumura, H.; Moriyama, M.; Yokosuka, O.; Omata, M. HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b. Hepatol. Int. 2015, in press.
    • (2015) Hepatol. Int
    • Hirotsu, Y.1    Kanda, T.2    Tsumur, H.3    Oriyam, M.4    Yokosuk, O.5    Omata, M.6
  • 37
    • 42949167169 scopus 로고    scopus 로고
    • The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob
    • McCown, M.F.; Rajyaguru, S.; le Pogam, S.; Ali, S.; Jiang, W.R.; Kang, H.; Symons, J.,Cammack, N.; Najera, I. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob. Agents Chemother. 2008, 52, 1604–1612.
    • (2008) Agents Chemother , vol.52 , pp. 1604-1612
    • McCown, M.F.1    Rajyaguru, S.2    Le Pogam, S.3    Ali, S.4    Jiang, W.R.5    Kang, H.6    Symons, J.7    Cammack, N.8    Najera, I.9
  • 38
    • 84888210472 scopus 로고    scopus 로고
    • Antiviral therapy for “difficult-to-treat” hepatitis C virus-infected patients
    • Kanda T.; Yokosuka, O.; Omata, M. Antiviral therapy for “difficult-to-treat” hepatitis C virus-infected patients. Chin. Med. J. 2013, 126, 4568–4574.
    • (2013) Chin. Med. J , vol.126 , pp. 4568-4574
    • Kanda, T.1    Yokosuka, O.2    Omata, M.3
  • 40
    • 84921909959 scopus 로고    scopus 로고
    • Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis
    • Zeuzem, S.; Soriano, V.; Asselah, T.; Gane, E.J.; Bronowicki, J.P.; Angus, P.; Lohse, A.W.; Stickel, F.; Müllhaupt, B.; Roberts, S., et al. Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis. Antimicrob. Agents Chemother. 2015, 59, 1282–1291.
    • (2015) Antimicrob. Agents Chemother , vol.59 , pp. 1282-1291
    • Zeuzem, S.1    Soriano, V.2    Asselah, T.3    Gane, E.J.4    Bronowicki, J.P.5    Angus, P.6    Lohse, A.W.7    Stickel, F.8    Müllhaupt, B.9    Roberts, S.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.